ReviewGut and liver2023
SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes.
Review in Gut and liver, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study.Clinical and molecular hepatology · 2026Article
- Assessing the Long-Term Impact of the COVID-19 Pandemic on Hospital Outcomes in Patients with Decompensated Liver Cirrhosis.Medicina (Kaunas, Lithuania) · 2026Article
- Liver-Related COVID-19 Consequences: Dynamics of Liver Health in 2.5 Years.Journal of clinical medicine · 2025Article
- Association between single-nucleotide polymorphism rs868875 of CLEC4M gene and clinical severity of COVID-19 in a Brazilian population.Immunogenetics · 2025Article
- COVID-19 and chronic liver disease: results from the 1219 patients French registry.Scientific reports · 2025Article
- Altered liver hemodynamics in patients with COVID-19: a cross sectional study.Journal of ultrasound · 2025Article
- Comprehensive immune profiling and predictive modelling of paediatric acute hepatitis of unknown aetiology from a Spanish cohort.Frontiers in immunology · 2025Article
- Association between ursodeoxycholic acid use and COVID-19 in individuals with chronic liver disease: a nationwide case-control study in South Korea.Virology journal · 2024Article
- The Silent Syndrome of Long COVID and Gaps in Scientific Knowledge: A Narrative Review.Viruses · 2024Review
- Article
- COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?International journal of molecular sciences · 2024Review
- Liver abnormalities following SARS-CoV-2 infection in children 1 to 10 years of age.Family medicine and community health · 2024Article
- Identification of shared pathogenetic mechanisms between COVID-19 and IC through bioinformatics and system biology.Scientific reports · 2024Article
- Effects of COVID-19 on the Liver and Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta and Non-Delta Variants: An Analysis in a Single Centre.Pharmaceuticals (Basel, Switzerland) · 2023Article
- COVID-19 + Cirrhosis = Excess Hospital Confinement, Excess Casualties.Digestive diseases and sciences · 2023Article
- COVID-19 and the Liver: A Complex and Evolving Picture.Hepatic medicine : evidence and research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
The impact of the coronavirus disease 2019 (COVID-19) pandemic has been immense, and it continues to have lasting repercussions. While the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus primarily infects the respiratory system, other organ systems are affected, including the liver. Scientific knowledge on the role of SARS-CoV-2 infection and liver injury has evolved rapidly, with recent data suggesting specific hepatotropism of SARS-CoV-2. Moreover, additional concerns have been raised in regard to long-term liver damage, related to emerging cases of post-COVID-19 cholangiopathy and chronic cholestasis. Great effort has also been focused on studying how specific subpopulations with chronic medical conditions might be disproportionately impacted by COVID-19. One such population includes individuals with chronic liver disease (CLD) and cirrhosis, with an expanding body of research indicating these patients being particularly susceptible to adverse outcomes. In this review, we provide an updated summary on the current pathogenesis and mechanism of liver injury in the setting of SARS-CoV-2 infection, the association between health outcomes and SARS-CoV-2 infection in patients with CLD, and the unique consequences of the COVID-19 pandemic on the routine care of patients with CLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.